1384277-05-7

Basic information

• Product Name: Cyclopropanol, 2-(4-penten-1-yl)-,(1R,2R)-rel-
• Synonyms: Cyclopropanol, 2-(4-penten-1-yl)-,(1R,2R)-rel-
• CAS NO: 1384277-05-7
• Molecular Weight: 126.199
• Mol File: 1384277-05-7.mol

Chemical Properties

• CAS DataBase Reference: Cyclopropanol, 2-(4-penten-1-yl)-,(1R,2R)-rel-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanol, 2-(4-penten-1-yl)-,(1R,2R)-rel-(1384277-05-7)
• EPA Substance Registry System: Cyclopropanol, 2-(4-penten-1-yl)-,(1R,2R)-rel-(1384277-05-7)

Safety Data

• Hazardous Substances Data: 1384277-05-7(Hazardous Substances Data)

Upstream product

• 1026200-23-6 trimethyl{[(1S,2S)-2-pent-4-en-1-ylcyclopropyl]oxy}silane 
• 4117-09-3 7-bromo-hept-1-ene 
• 109-94-4 formic acid ethyl ester 
• 124471-62-1 (E)-(hepta-1,6-dien-1-yloxy)trimethylsilane 

Relevant articles and documents

METHODS AND INTERMEDIATES FOR THE PREPARATION OF MACROLACTAMS

The present invention relates to synthetic processes useful in the preparation of macrolactams that inhibit hepatitis C virus (HCV), specifically macrolactam compounds that inhibit the HCV NS3 protease activity and have application in the treatment of conditions caused by HCV. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

INHIBITORS OF HEPATITIS C VIRUS

Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor

A new class of HCV NS3/4a protease inhibitors containing a P2 to P4 macrocyclic constraint was designed using a molecular modeling-derived strategy. Building on the profile of previous clinical compounds and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing. These studies led to the identification of clinical candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clinically relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.

Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.

HCV NS3 PROTEASE INHIBITORS

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.